Technology Available for License

Technology Available for License This page informs others of patented inventions from several institutions with commercial potential

Biologics, Drugs, Drug Development and Discovery, Diagnostics, Anitbodies, Software, Materials Science, Engineering, etc.

05/24/2024

Read OTL Intellectual Property newsletter

The 2024 Office of Technology Licensing (OTL) Intellectual Property newsletter is now available. This issue covers an introduction to Lisa Jordan and Bethany Furr in their new roles, licensing and patenting activities, forms on the hub, the FDA approval of two hemophilia drugs and more.

Sign up for future newsletters!

Soon after opening in the 1960’s, St. Jude leadership discussed what could be done to help heal the wounds of racial div...
04/11/2024

Soon after opening in the 1960’s, St. Jude leadership discussed what could be done to help heal the wounds of racial division. The conversation led them to open a clinic for underserved children, staffing it with volunteers. It was quickly evident that many of the clinic’s patients were severely malnourished.

St. Jude partnered with a local community organization called Memphis Area Project South (MAP-South) to provide food to families in desperate need. MAP-South set up a warehouse across the street from the Lorraine Motel and distributed surplus food from the U.S. Department of Agriculture. This program dramatically increased our scientific knowledge about the impact of malnutrition on young children, one-quarter of low-income children were anemic, one-third had parasitic infections, 50% showed signs of stunted growth and 15% were dramatically below the average height and weight for their age. Door by door participants were recruited, picked up to be brought in, and served meals and clinically evaluated at St. Jude. MAP-South also offered social services support. Sometimes, that was the only full, nutritious meal the child received that day.

After a year of distributing food, organizers realized that the program was not effectively reaching the population most in need: children under age 2. St. Jude responded with a new initiative, enrolling thousands of babies in the poverty-stricken area in a “well baby care program.” The families were provided with specially enriched baby formula on a prescription basis.

The results of the effort were extraordinary. When properly fed, the poor infants grew at the same rate as middle-class children. Anemia plummeted to 8% in treated infants. The program showed that infant malnutrition could be eliminated at a cost of just 71 cents a day per child.

The achievement eventually spurred development of the federal Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). Today, WIC meets the nutritional needs of 8.2 million people every month and is widely viewed as one of the most successful nutrition programs of all time. More information here: https://www.stjude.org/research/progress/2020/african-american-clinical-researcher-breaks-barriers.html

Please consider watching the “Prescription Food” documentary by WMC-TV

Read how this African American clinician and researcher has broken medical and community barriers down for the past 40 years.

12/11/2023

Tomorrow! December 12, 2023
Is Technology Transfer Professionals Day, the 43rd anniversary of the signing of the Bayh-Dole Act, enabling Technology Transfer! Celebrated along with the MemBioBreak Year End Holiday Party at Flip Side Memphis with both food and drink. It's a pinball machine bar and restaurant across from Crosstown Concourse at 1349 Autumn Ave. They have a pinball tournament at 7pm, so those who want to continue enjoying that atmosphere can, but I will lead the rest to Crosstown Brewing Company @6:45pm to continue the celebration. We look forward to seeing our Technology Transfer Collogues and invite the Graduate Students, Post-Doctoral Associates, Researchers, Innovators, and others to network and learn more about the profession!

Coming? Please email me to RSVP chad.riggs@stjude.org

Remember that's
at Flip Side Memphis
@6:45pm Crosstown Brewing Company
RSVP and see you then!

I heard about this news from Ohio State on fall break last week, and the combination (intranasal/mmr/covid) just seemed ...
10/17/2023

I heard about this news from Ohio State on fall break last week, and the combination (intranasal/mmr/covid) just seemed unique and maybe best case scenario. (and also interesting because adding H1N1 to trivalent flutist was a dud)

Incorporating a coronavirus antigen into MMR vaccine to produce COVID-19 immunity in kids

New research has advanced COVID-19 vaccine work in several ways: using a modified live attenuated mumps virus for delivery, showing that a more stable coronavirus spike protein stimulates a stronger immune response, and suggesting a dose up the nose has an advantage over a shot.

Researchers at St. Jude identified DNA Sequences Unique to Cancer Cells (SJ-21-0046).  Subtle differences in the oncogen...
09/06/2023

Researchers at St. Jude identified DNA Sequences Unique to Cancer Cells (SJ-21-0046). Subtle differences in the oncogenic fusion mutations were discovered in a small group of pediatric patients with relapsed acute myeloid leukemia (AML), and improved clinical diagnostics were developed to better explained survival outcomes, which will help physicians choose more personalized and effective treatments for patients in the future.

Oncogenic fusions formed through chromosomal rearrangements are hallmarks of childhood cancer that define cancer subtype, predict outcome, persist through treatment, and can now be therapeutic targets as scientists at St. Jude Children’s Research Hospital comprehensively characterized oncogenic fusions in pediatric cancer, providing proof-of-principle for genetic engineering and gene editing therapies.

Researchers at St. Jude discovered this genome-editing- and etiology-based strategy for cancer therapy. The invention includes an algorithm for identifying cryptic exons arising from aberrant splicing unique to cancer cells and can be applied to fusion-positive cancer patients with neo-splicing that introduced cryptic exons. Because these neo-splice sites (or the cryptic exons) are not used in normal cells, therapies targeting these sites are expected to be nontoxic to normal cells and theoretically have an infinite therapeutic window.

Recently published related scientific references:

Liu, Y., Klein, J., Bajpai, R. et al. Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. Nat Comm. 14, 1739 (2023). https://doi.org/10.1038/s41467-023-37438-4

Press release on the paper above: https://www.stjude.org/media-resources/news-releases/2023-medicine-science-news/tool-targets-cancer-causing-fusions-weak-spot.html

Learn how St. Jude research cataloguing the oncogenic fusions in pediatric acute myeloid leukemia (AML) could lead to cures using genome editing (CRISPR-Cas9).

08/24/2023

NEW! SJ-21-0018, Combination DNMT3a KO and IL10 signaling Researchers at St. Jude identified an approach for treating T cells with IL-10 and/or enhancing IL-10 signaling pathways to preserve the cell’s multipotent state during manufacturing and persistence after therapeutic administration. It can be used to preserve the developmental potential of T cells used for adoptive cellular therapies during product manufacturing and/or supplement the T cell response during application and prevent anergic programs acquired during chronic antigen stimulation.

Retention of a multipotent developmental status in T cells utilized for immune checkpoint blockade and CAR T cell therapies has been shown to be coupled to positive clinical outcomes. The researchers demonstrated in preclinical models that combining IL-10 with approaches that block acquisition of tolerance epigenetic programs will enable less differentiated cells to persist in therapeutic settings. In addition to supplementing T cells with exogenous IL-10 during CAR T cell manufacturing in the tumor microenvironment (ICB or CAR T cells), T cells used for adoptive cellular therapies could be engineered to express their own IL-10 to support their own multipotent preservation and the other T cells in the surrounding environment. Lastly, but not limited to, patients could receive IL-10 post T cell infusion to preserve multipotency or adoptive T cell therapy could be combined with gene therapy approaches to express IL-10 within tumors (or other tissues) including oncoloytic viruses or non-viral DNA/RNA delivery systems including nanoparticles.

The approach was successful for CAR T cells to preserve their multipotency, it could be readily applied to other immune cell populations in which multipotency programs are critical including, but not limited to, virus- and/or tumor-specific T cells that recognize their targets through conventional T cell receptors (TCRs), and immune cells that express other molecules than CARs to render them antigen-specific, including, but not limited to, bispecific antibodies or T cell antigen couplers (TACs).

The recent paper is being read and cited at a high rate:
Prinzing et al., "Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity," Sci. Transl. Med.13, eabh0272 (2021), 17 November 2021, Vol 13, Issue 620. DOI: 10.1126/scitranslmed.abh0272

https://www.stjude.org/research/why-st-jude/shared-resources/technology-licensing/technologies/combination-dnmt3a-ko-and-il10-signaling-sj-21-0018.html?utm_source=ActiveCampaign&utm_medium=email&utm_content=T+Cell+Biologic+Related+Technologies&utm_campaign=T+Cell+Biologic+Therapy+Related+Technologies+10%2F2022+%28Copy%29+%28Copy%29&vgo_ee=jY7TzI36Rc%2Flh0ZcZTtsDnKGl7BgrS1Sl1W0nOSswgS80gPPSg%3D%3D%3A8pfXjTNQKDesIR77A8%2BWgCmlVoyaM%2BeD

NEW Publication! SJ-20-0020: Method to Activate Fetal Hemoglobin Expression, where researchers at St. Jude recreated the...
08/24/2023

NEW Publication! SJ-20-0020: Method to Activate Fetal Hemoglobin Expression, where researchers at St. Jude recreated the naturally occurring point mutation in the human γ-globin gene promoter at the position -175 (T-C) in erythroid progenitor cell line (HUDEP-2) and in adult hematopoietic stem cells (HSCs) to induced therapeutic levels of fetal globin in differentiated erythroid cells. This invention can be used to manipulate the HSCs from sickle cell disease or β-thalassemia patients to induce fetal hemoglobin which ameliorates the disease severity.

Mayuranathan, T., Newby, G.A., Feng, R. et al. Potent and uniform fetal hemoglobin induction via base editing. Nat Genet 55, 1210–1220 (2023). https://doi.org/10.1038/s41588-023-01434-7

https://www.stjude.org/research/why-st-jude/shared-resources/technology-licensing/technologies/method-to-activate-fetal-hemoglobin-expression-sj-20-0020.html?utm_source=ActiveCampaign&utm_medium=email&utm_content=T+Cell+Biologic+Related+Technologies&utm_campaign=T+Cell+Biologic+Therapy+Related+Technologies+10%2F2022+%28Copy%29+%28Copy%29&vgo_ee=jY7TzI36Rc%2Flh0ZcZTtsDnKGl7BgrS1Sl1W0nOSswgS80gPPSg%3D%3D%3A8pfXjTNQKDesIR77A8%2BWgCmlVoyaM%2BeD

This invention can be used to manipulate the HSCs from sickle cell disease or β-thalassemia patients to induce fetal hemoglobin which ameliorates the disease severity.

08/24/2023

NEW Publication! SJ-19-0003: A novel approach for reducing the incorporation of contaminating DNA in AAV gene therapy preparations has a publuished patent application and a 2022 publication listing many advantages, such as the post infection transcriptional activity of the contaminants from this source. Another paper (2023) covers the profile, abundance, and post-treatment consequences of nucleic acid impurities within rAAV, and cover strategies that have been developed to improve rAAV purity.
20230203535 (uspto.gov)

https://www.stjude.org/research/why-st-jude/shared-resources/technology-licensing/technologies/promoter-modification-to-reduce-aav-contamination-sj-19-0003.html?utm_source=ActiveCampaign&utm_medium=email&utm_content=T+Cell+Biologic+Related+Technologies&utm_campaign=T+Cell+Biologic+Therapy+Related+Technologies+10%2F2022+%28Copy%29+%28Copy%29&vgo_ee=jY7TzI36Rc%2Flh0ZcZTtsDnKGl7BgrS1Sl1W0nOSswgS80gPPSg%3D%3D%3A8pfXjTNQKDesIR77A8%2BWgCmlVoyaM%2BeD

Hu14.18K322A (Hu14.18) for the treatment of High-Risk Neuroblastoma
08/08/2023

Hu14.18K322A (Hu14.18) for the treatment of High-Risk Neuroblastoma

Holmes Road shooting victim, suspect identified 1 hour ago ="Navigation" data-module-type="navigation"data-link-category="Navigation" data-module-type="navigation"data-link-category="Navigation" data-module-type="navigation"data-link-category="Navigation" data-module-type="navigation"data-link-categ...

https://www.biopharma-reporter.com/Article/2023/08/01/renaissance-pharma-inks-partnership-with-st.-jude-children-s-resea...
08/08/2023

https://www.biopharma-reporter.com/Article/2023/08/01/renaissance-pharma-inks-partnership-with-st.-jude-children-s-research-hospital

Hu14.18, a humanised antibody in development by the hospital for the treatment of newly diagnosed high-risk neuroblastoma.

Renaissance Pharma, a company focused on the development of life changing therapies in pediatric rare disease, has entered into an exclusive license agreement with St. Jude Children’s Research Hospital for Hu14.18, a humanised antibody in development by the hospital for the treatment of newly diag...

Address

262 Danny Thomas Place
Memphis, TN
38105

Alerts

Be the first to know and let us send you an email when Technology Available for License posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Technology Available for License:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram